Selection of aptamers specific for glycated hemoglobin and total hemoglobin using on-chip SELEX.

Blood glycated hemoglobin (HbA1c) levels reflecting average glucose concentrations over the past three months are fundamental for the diagnosis, monitoring, and risk assessment of diabetes. It has been hypothesized that aptamers, which are single-stranded DNAs or RNAs that demonstrate high affinity to a large variety of molecules ranging from small drugs, metabolites, or proteins, could be used for the measurement of HbA1c. Aptamers are selected through an in vitro process called systematic evolution of ligands by exponential enrichment (SELEX), and they can be chemically synthesized with high reproducibility at relatively low costs. This study therefore aimed to select HbA1c- and hemoglobin (Hb)-specific single-stranded DNA aptamers using an on-chip SELEX protocol. A microfluidic SELEX chip was developed to continuously and automatically carry out multiple rounds of SELEX to screen specific aptamers for HbA1c and Hb. HbA1c and Hb were first coated onto magnetic beads. Following several rounds of selection and enrichment with a randomized 40-mer DNA library, specific oligonucleotides were selected. The binding specificity and affinity were assessed by competitive and binding assays. Using the developed microfluidic system, the incubation and partitioning times were greatly decreased, and the entire process was shortened dramatically. Both HbA1c- and Hb-specific aptamers selected by the microfluidic system showed high specificity and affinity (dissociation constant, Kd = 7.6 ± 3.0 nM and 7.3 ± 2.2 nM for HbA1c and Hb, respectively). With further refinements in the assay, these aptamers may replace the conventional antibodies for in vitro diagnostics applications in the near future.

[1]  G. Mayer The chemical biology of aptamers. , 2009, Angewandte Chemie.

[2]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[3]  Sang-Hoon Lee,et al.  DNA-enrichment microfluidic chip for chromatin immunoprecipitation. , 2009, Analytical chemistry.

[4]  A. Heeger,et al.  Micromagnetic selection of aptamers in microfluidic channels , 2009, Proceedings of the National Academy of Sciences.

[5]  Seung Soo Oh,et al.  Generation of highly specific aptamers via micromagnetic selection. , 2009, Analytical chemistry.

[6]  L. Gold,et al.  Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.

[7]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[8]  Birgit Cech,et al.  A DNA aptamer with high affinity and specificity for therapeutic anthracyclines. , 2008, Analytical biochemistry.

[9]  S. Jayasena Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[10]  Gwo-Bin Lee,et al.  A suction-type microfluidic immunosensing chip for rapid detection of the dengue virus , 2011, Biomedical microdevices.

[11]  E. Kilpatrick,et al.  Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus , 2008, Journal of Clinical Pathology.

[12]  R. Little,et al.  Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. , 2011, Clinical chemistry.

[13]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[14]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[15]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[16]  A. Farmer,et al.  Point-of-care testing for Hb A1c in the management of diabetes: a systematic review and metaanalysis. , 2011, Clinical chemistry.

[17]  James Albers,et al.  Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. , 2006, Diabetes care.

[18]  Vivien Marx,et al.  Finding the right antibody for the job , 2013, Nature Methods.

[19]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[20]  Glen Hybarger,et al.  A microfluidic SELEX prototype , 2006, Analytical and bioanalytical chemistry.

[21]  E. Lenters-Westra,et al.  Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. , 2010, Clinical chemistry.

[22]  J. Mordes,et al.  Implications of using hemoglobin A1C for diagnosing diabetes mellitus. , 2011, The American journal of medicine.

[23]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[24]  M. Steffes,et al.  Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. , 2001, Clinical chemistry.

[25]  Å. Lernmark,et al.  Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus , 2011, Diabetes Care.

[26]  S. Cherian,et al.  Intravascular large B cell lymphoma presenting in a liver explant , 2008, Journal of Clinical Pathology.

[27]  Gwo-Bin Lee,et al.  Screening of Aptamers on Microfluidic Systems for Clinical Applications , 2012, Sensors.

[28]  Kwang-Cheol Lee,et al.  An electrochemical impedance biosensor with aptamer-modified pyrolyzed carbon electrode for label-free protein detection , 2008 .

[29]  R. Stewart,et al.  Quantitative selection and parallel characterization of aptamers , 2013, Proceedings of the National Academy of Sciences.

[30]  Gwo-Bin Lee,et al.  An integrated microfluidic system for rapid screening of alpha-fetoprotein-specific aptamers. , 2012, Biosensors & bioelectronics.

[31]  R. Little,et al.  The long and winding road to optimal HbA1c measurement. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[32]  David B Sacks,et al.  A new look at screening and diagnosing diabetes mellitus. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.